Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pulmonary Arterial Hypertension: full-pipeline trial registry
21 of 64 indexed Pulmonary Arterial Hypertension trials are currently recruiting.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 21 currently recruiting · #215 of 28,707 conditions by registered trial count
Pulmonary Arterial Hypertension: 64 US clinical trials tracked, 21 recruiting.
Pulmonary Arterial Hypertension is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 21 of them currently open to new participants. 18 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Actelion, running 7 of these trials.
Enrollment posture brief
Registry condition pulmonary-arterial-hypertension
OPEN 21 | RECR 33% | LATE 18 | EARLY 22 | RANK #215 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus, Type 1 (33% recruiting · 119 trials)
Pulmonary Arterial Hypertension lists 21 open slots (33% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pulmonary Arterial Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pulmonary Arterial Hypertension is recruiting below its size-band peers.
21 of 64 indexed trials (32.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pulmonary Arterial Hypertension trials is spread across many organizations.
Actelion accounts for 7 of 64 trials (10.9%). 41 distinct sponsors appear on at least one study for this condition label.
-
Most Pulmonary Arterial Hypertension trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 64 trials that report a genuine target (sentinel values excluded). 45 of those (70.3%) plan for fewer than 100 participants.
-
Pulmonary Arterial Hypertension research is mostly interventional.
51 interventional and 13 observational studies make up this index (79.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 1 of 2
Rutgers University Study of the Genetics of Pulmonary Hypertension
Rutgers, The State University of New Jersey
NCT07217522
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Duke University
NCT04278404
Pulmonary Hypertension Association Registry
Pulmonary Hypertension Association
NCT04071327
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
New York Medical College
NCT02249923
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Merck Sharp & Dohme
NCT07218029
Pulmonary Hypertension Biorepository and Registry
University of Kansas Medical Center
NCT04808596
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Vanderbilt University Medical Center
NCT05464095
PET Image in PAH Patients
Stephen Y. Chan
NCT05452889
Spironolactone for Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)
NCT01712620
Xenon MRI Pulm Hypertension
Bastiaan Driehuys
NCT04991454
Repurposing Valsartan May Protect Against Pulmonary Hypertension
University of Washington
NCT06053580
Mobile Health Intervention to Improve Exercise in Pediatric PH
Vanderbilt University Medical Center
NCT06549452
A Study of Pulmonary Hypertension Peripheral Limitations
Mayo Clinic
NCT05968859
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Merck Sharp & Dohme
NCT05587712
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
Aria CV
NCT04555161
Pulmonary Hypertension SOLAR
Bastiaan Driehuys
NCT04778046
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
University of Minnesota
NCT06481852
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
University of Arizona
NCT04062565
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Bastiaan Driehuys
NCT06104228
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
V-Wave
NCT03838445
129 Xenon Imaging in Patients Treated With Sotatercept
Bastiaan Driehuys
NCT06351345
Pulmonary Vascular Disease Phenomics Program PVDOMICS
The Cleveland Clinic
NCT02980887
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Actelion
NCT04273945
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
GB002
NCT06274801
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
United Therapeutics
NCT03045029
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
Merck Sharp & Dohme
NCT06925750
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
Pfizer
NCT06137742
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Insmed Incorporated
NCT05649748
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
GB002, Inc., a wholly owned subsidiary of Gossamer Bio
NCT04816604
DelIVery for Pulmonary Arterial Hypertension (PAH) & Continued Support Study
Medtronic Cardiac Rhythm and Heart Failure
NCT01321073
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
Stanford University
NCT03893500
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Actelion
NCT03492177
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics
NCT05203510
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
The Cleveland Clinic
NCT03288025
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
Mayo Clinic
NCT06409026
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
Liquidia Technologies
NCT04691154
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
University of Pennsylvania
NCT06543745
Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension
University of Kansas Medical Center
NCT05339386
The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI
Prisma Health-Upstate
NCT06907693
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
United Therapeutics
NCT01266265
A Registry for Patients Taking Uptravi
Actelion
NCT03278002
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Actelion
NCT02558231
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Merck Sharp & Dohme
NCT06664801
Novel Screening Strategies for Scleroderma PAH
University of Michigan
NCT01959815
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
Actelion
NCT03078907
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00323297
Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
Northwell Health
NCT00566423
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Gilead Sciences
NCT00617305
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Lung Biotechnology PBC
NCT00989963
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
United Therapeutics
NCT03497689
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 16 |
| Phase 3 | 7 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Pulmonary Arterial Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pulmonary Arterial Hypertension trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pulmonary Arterial Hypertension page
64 registered trials, 21 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 21 Pulmonary Arterial Hypertension trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Actelion sponsors the most Pulmonary Arterial Hypertension trials on record, review their full trial history before evaluating a specific study. See Actelion's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pulmonary Arterial Hypertension condition card totals 64 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.